Rafael Pharmaceuticals

    OverviewSuggest Edit

    Rafael Pharmaceuticals is a clinical-stage metabolic oncology therapeutics company. It develops cancer therapies for a range of intractable forms of the disease including AML, Burkitts and pancreatic cancer. The company offers CPI-613, a drug candidate that targets enzymes involved in cancer cell energy metabolism and located in the mitochondria of cancer cells.
    TypePrivate
    Founded2000
    HQCranbury Township, NJ, US
    Websiterafaelpharma.com
    Employee Ratings3.4

    Latest Updates

    Employees (est.) (Jul 2021)33
    Cybersecurity ratingAMore

    Key People/Management at Rafael Pharmaceuticals

    Sanjeev Luther

    Sanjeev Luther

    President and Chief Executive Officer, Director
    Paul Bingham

    Paul Bingham

    Vice President, Research
    Aaron Drillick

    Aaron Drillick

    Director
    Robert Shorr

    Robert Shorr

    Chief Scientist and Co-Founder, Director
    José Octávio Costa Filho

    José Octávio Costa Filho

    Chief Medical Officer
    Mike Hu

    Mike Hu

    Chief Development Officer
    Show more

    Rafael Pharmaceuticals Office Locations

    Rafael Pharmaceuticals has offices in Cranbury Township and Houston
    Cranbury Township, NJ, US (HQ)
    1 Duncan Dr, Cranbury
    Houston, TX, US
    1515 Holcombe Blvd
    Show all (2)

    Rafael Pharmaceuticals Financials and Metrics

    Summary Metrics

    Founding Date

    2000

    Rafael Pharmaceuticals Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    94/100

    SecurityScorecard logo

    Rafael Pharmaceuticals Online and Social Media Presence

    Embed Graph

    Rafael Pharmaceuticals News and Updates

    Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

    CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive outcome from its preplanned interim futility analysis of its pivotal Phase 3 trial (ARMADA 2000) of …

    Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress

    CRANBURY, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that data on its lead compound, devimistat, has been selected for an oral presentation at the 2021 Euro…

    Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company

    NEWARK, N.J. and CRANBURY, N.J., June 21, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL) announced that it has entered into a merger agreement with Rafael Pharmaceuticals, Inc., a privately held, late-stage clinical oncology company focused on cancer metabolism-based therapeutics....

    Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

    CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meetin…

    Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancer Company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancer

    Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

    President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20 President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D…
    Show more

    Rafael Pharmaceuticals Frequently Asked Questions

    • When was Rafael Pharmaceuticals founded?

      Rafael Pharmaceuticals was founded in 2000.

    • Who are Rafael Pharmaceuticals key executives?

      Rafael Pharmaceuticals's key executives are Sanjeev Luther, Paul Bingham and Aaron Drillick.

    • How many employees does Rafael Pharmaceuticals have?

      Rafael Pharmaceuticals has 33 employees.

    • Who are Rafael Pharmaceuticals competitors?

      Competitors of Rafael Pharmaceuticals include Pharmacyclics, 3sbio and Takeda Oncology.

    • Where is Rafael Pharmaceuticals headquarters?

      Rafael Pharmaceuticals headquarters is located at 1 Duncan Dr, Cranbury, Cranbury Township.

    • Where are Rafael Pharmaceuticals offices?

      Rafael Pharmaceuticals has offices in Cranbury Township and Houston.

    • How many offices does Rafael Pharmaceuticals have?

      Rafael Pharmaceuticals has 2 offices.